Vox Nutrition vs SMP Nutra: Which Private Label Partner for Your Offer?

What does each company's stock catalog cover?

SMP Nutra prices its stock catalog in writing: $4–$20 per unit for private-label formulas and $5–$30 per unit for custom builds, both inclusive of bottling, testing, seals and labels but not shipping, per its published FAQ. That range covers the standard six formats — capsules, tablets, powders, softgels, gummies and liquids — at its usual 2,500–5,000-bottle-per-SKU run size.

Vox Nutrition does not publish an equivalent price table in the materials checked for this page. Treat any per-unit figure a sales rep quotes you as a starting point, not a floor, and get it in writing before you model margin against a network payout. The gap itself is a data point: a manufacturer that prices publicly is easier to shop against competitors before you ever get on a call.

Catalog depth matters less than what you're allowed to do with the formula afterward. Under true private label, the manufacturer owns the formula and you cannot move production to a second supplier without renegotiating; under contract manufacturing, ownership passes to the brand only if the development agreement says so in writing — a distinction worth understanding before you compare white label, private label and contract manufacturing structures side by side.

How do their MOQs and price breaks compare?

SMP Nutra's minimum order is enforced at the equipment level, not just on paper. Its FAQ states a hard floor of 1,000 bottles per SKU that cannot be split across different products, above a standard stock MOQ of 2,500–5,000 bottles and custom-formula MOQs that range from 150,000 pieces for capsules up to 1,000,000 pieces for gummies.

• The MOQ floor reads as a constraint, but on-demand ordering usually costs more per unit, not less
• Zero-minimum fulfillment models run roughly 1.8x–2.5x the per-unit price of buying at manufacturing MOQ once bulk discounts are backed out, so a shop that forces a 1,000-bottle commitment can end up cheaper per bottle than one that lets you order ten
• A standard 60-count capsule SKU with common ingredients runs about $3.50–$4.50 per bottle at a 1,500-unit first order, $2.50–$3.50 at 5,000 units, $2.00–$3.00 at 10,000 units and $1.50–$2.50 at 25,000 units, per Inventory Ready's cost model — per-unit cost roughly halves between a first-run MOQ and a 25,000-bottle run

Which formats — gummies, softgels, liquids — does each handle best?

Capsules and tablets are the cheapest formats to manufacture at scale, and gummies and liquids the most expensive — a pattern that holds across manufacturers generally, not just SMP Nutra or Vox Nutrition specifically. A published per-format cost table for a 60-count bottle at roughly 5,000-unit runs lists capsules and tablets at $2.50–$5.00, powders at $3.00–$6.00, softgels at $3.50–$7.00, gummies at $4.00–$8.00+ and liquids at $5.00–$10.00 per bottle, per Inventory Ready's cost guide.

Gummies carry the sharpest MOQ cliff between stock and custom. SMP Nutra lists stock gummy runs starting as low as 1,000 bottles, but a custom gummy formula jumps to 500,000–1,000,000 pieces — 8,333 to 16,666 bottles at 60-count, roughly a tenfold increase — per SMP Nutra's own custom gummy manufacturing page. Budget for that jump before you commit to a proprietary blend.

Format also decides how much inventory risk you're carrying. Gummies run about a year of shelf life, up to two in ideal storage, and fuse into a single mass above 90°F; probiotics need real-time CFU viability testing across roughly 6–24 months; capsules are the most stable format and the one manufacturers default to for longevity, per stability-testing guidance from Vitaquest. Order gummy and probiotic runs in months of forecasted sell-through, not years.

How do lead times compare for stock versus custom runs?

Custom formulas take roughly twice as long to land as private-label stock runs, which in turn take longer than pure stock formulas. Published industry ranges put stock-formula turnaround at 2–4 weeks, private label at 4–8 weeks and custom formulation at 8–16 weeks, with capsules and tablets fastest at 4–8 weeks and gummies slower at 8–12 weeks, per Inventory Ready's lead-time data.

SMP Nutra publishes a tighter number than the industry range: 8–10 weeks for a new customer counted from the day it receives your label artwork, dropping to 6–8 weeks on a reorder once labels are already on file, per its FAQ. Vox Nutrition's equivalent commitment was not in the materials checked for this page — get a written date range tied to a specific SKU and format before you build a launch calendar around it.

The usual cause of slippage isn't the manufacturer stalling — it's raw-material sourcing on specialty or imported ingredients, plus the 21 CFR 111.75 requirement that every unique incoming lot get identity-tested, which adds a minimum 5–10 days on its own. Q3 and Q4 capacity crunches compound both. Ask whichever partner you choose whether your ingredients are already in stock; that single question moves your ship date by weeks.

What do customer reviews say about quality and communication?

Neither company's aggregate customer-satisfaction data was in the source set checked for this page, and star ratings on third-party sites shift fast enough that any figure printed here would go stale within months. The more durable signal is what a manufacturer will hand you unprompted: current certificates of analysis, its facility's registration status, and direct references from brands running product today.

A standard contaminant COA covers four heavy metals — arsenic, cadmium, lead and mercury — typically by ICP-MS, alongside a microbiological panel covering aerobic plate count, yeast and mold, E. coli, Salmonella and Staphylococcus, per testing guidance from Anresco Laboratories and Alkemist Labs. Ask for a COA from the actual batch you're buying, not a specimen sample from the manufacturer's marketing deck; the two aren't required to match.

'FDA registered facility' is a claim worth reading carefully. Registration under 21 CFR 1.225 is an obligation, not an endorsement — FDA states plainly that it does not approve manufacturing facilities independently and that registration 'does not denote approval of the establishment.' A manufacturer that leans on that phrase in its sales copy isn't lying, but it isn't telling you much either.

Which one suits a first white label run versus a scaling offer?

A first white-label run favors whichever partner will confirm its actual floor in writing and hold to a stock formula. SMP Nutra's published floor sits at 1,000 bottles per SKU minimum with no splitting across products, above its 2,500–5,000-bottle standard stock MOQ — a real commitment for a first test, not a token one. Whichever floor you accept, size your first SKU count against the payout structure of whichever affiliate network you intend to run it through, since network minimums and manufacturing MOQ interact more than most first-time buyers expect.

Scaling changes the math entirely. Once you're confident in a formula, volume tiers reward committing further out, since per-bottle cost on a standard capsule SKU roughly halves moving from a 1,500-unit first run to a 25,000-unit run — so a manufacturer that quoted a slightly higher first-run price can still win on total cost once you're reordering at volume. This is also where lead-time reliability starts to matter more than sticker price, since a rebill offer running low on stock loses continuity a straight-sale test can absorb more easily.

Match the manufacturer to the offer type you're actually running, not the one you hope to run. A trial or rebill structure needs a partner who can guarantee reorder turnaround in writing, since a stockout mid-cycle costs you the recurring revenue the offer was built around; a straight-sale test can tolerate a slower, cheaper first batch while you find out whether the creative, the lander or the offer is the actual bottleneck before you commit to volume.

What should you get in writing before wiring the deposit?

Get formula ownership settled before anything else changes hands. Whether you or the manufacturer owns the formula and its IP depends entirely on the contract language, not on whether the arrangement is called private label or contract manufacturing — under true contract manufacturing you own it only if the agreement explicitly says so, per Atrium Sci's breakdown of the distinction.

None of this replaces reading the manufacturer's own contract. It just tells you which clauses to look for before you wire a deposit that funds tooling, stability testing or a custom mold you can't easily walk away from — one-time custom setup costs commonly add 20–40% on top of the quoted per-unit price, per Inventory Ready's cost breakdown, and you want that number before it shows up on an invoice instead of a quote.

• Formula and IP ownership clause, stated explicitly — don't assume private label means you own it
• A COA commitment tied to the specific batch you receive, covering heavy metals, microbiological panel and label-claim potency
• A written lead-time range by SKU and format, plus what happens to your ship date if an ingredient isn't in stock
• Confirmation of which entity sits on the FDA facility registration, and a clear statement that registration isn't being sold to you as approval
• Record-retention terms — cGMP under 21 CFR 111.605 requires manufacturers to hold batch records 1 year past shelf-life date or 2 years past last distribution, so ask what happens to your records if you switch suppliers
• Landed-cost exposure if any component is imported — the Tax Foundation puts 2026's average effective US tariff rate near 6.6%, and the picture has shifted more than once this year

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Daily Intel research methodology, Competitor Creative Fatigue: How to Spot It Outside, 3:2:2 Method for Facebook Ads: Setup, Math, Limits, Quantos Dias Testar um Criativo no Meta Ads (A Regra), Quando Pausar um Anúncio Que Não Converte: Critérios, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.